Inflammatory Bowel Disease (IBD) could be associated with Colorectal Cancer because it causes inflammation and, when it persists for many years, cells within the intestinal lining may become abnormal and, eventually, cancerous.

You may have an increased risk of cancer if you have severe ongoing inflammation

Your chances of developing Colorectal Cancer increase if you do get treatment for IBD.

Calprotectin as a non-specific marker of inflammation provides a direct indication for Colorectal Cancer.

Congratulations!

That's the correct answer!

Sorry! That´s not completely correct!

Please try again

Sorry! That's not the correct answer!

Please try again

Notice

Please select at least one answer

Supporting diagnosis for a patient with gastrointestinal symptoms by combining CALiaGold® and FOB Gold®

The patient presented with symptoms such as stomach pain and blood in stool which caused her to go for a check-up. The doctor provided her home sampling kits for FOB Gold^® and sequential testing of CALiaGold^®. After the samples were tested, laboratory results showed repeated, elevated calprotectin levels over a period of weeks. Moreover, the FOB Gold^® test also showed a positive result and the patient had to undergo a colonoscopy.

Subsequently, IBD and the CRC precursor stage with several non-advanced adenomas were detected after biopsies were taken. The patient underwent surgery to resect the parts of the colon affected by IBD, whereas the non-advanced adenomas were adequately removed during the endoscopic investigation.

From now on, the patient will undergo treatment for IBD and will be closely monitored by attending follow-up colonoscopies every 3 years (surveillance population).

References

[1] Lanas A. et al. (2023): Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study. United European Gastroenterol J (2023) 11(7): 692–699.

Key message: FOB Gold (hemoglobin, fHb) and CALiaGold (calprotectin, FC) results were used to develop a tool for identifying symptomatic patients at high risk for CRC who need urgent referral to colonoscopy, thus adding a cut-off of 150 μg/g of FC to both fHb thresholds (> 0 and ≥ 10), the sensitivity of fecal tests could be improved (to 97.1 % and 95.6 %).